Normal-Tension Glaucoma
Definition
A form of primary open-angle glaucoma in which characteristic optic nerve damage and visual field loss occur despite IOP consistently within the statistically normal range (≤ 21 mmHg).
Clinical Snapshot
Normal-tension glaucoma (NTG) is a form of POAG in which characteristic glaucomatous optic nerve damage and visual field loss occur despite IOP consistently ≤ 21 mmHg. It accounts for approximately 30–40% of POAG cases in Western populations and a higher proportion in Asian populations. NTG challenges the IOP-centric model of glaucoma and highlights the importance of IOP-independent mechanisms — vascular dysregulation, systemic hypotension, and neuroinflammation — in optic nerve disease.
Epidemiology
NTG accounts for 30–40% of POAG in Western populations and up to 90% in some Japanese studies. It is more common in women and in patients with systemic vascular conditions including migraine, Raynaud's phenomenon, and systemic hypotension.
Pathophysiology
IOP-independent mechanisms are central to NTG pathogenesis. Vascular dysregulation — impaired autoregulation of optic nerve head blood flow — is a key mechanism, particularly in patients with migraine and Raynaud's phenomenon. Nocturnal hypotension (excessive blood pressure dip during sleep) reduces optic nerve perfusion pressure. Sleep apnea causes intermittent hypoxia and IOP spikes. Neuroinflammation and mitochondrial dysfunction may also contribute.
Risk Factors
- Vascular dysregulation (migraine, Raynaud's phenomenon)
- Systemic hypotension, particularly nocturnal dipping
- Sleep apnea
- Female sex
- Japanese ancestry
- Disc hemorrhages (a strong risk factor for progression)
- Thin central corneal thickness
Clinical Presentation
Identical to POAG in terms of optic nerve and visual field findings — the distinction is IOP ≤ 21 mmHg on multiple measurements. Visual field defects in NTG tend to be more focal, deeper, and closer to fixation than in high-tension POAG. Disc hemorrhages are more common in NTG than in high-tension POAG.
Diagnostic Pearls
- Multiple IOP measurements at different times of day are required — a single normal reading does not exclude high-tension glaucoma.
- Evaluate for systemic vascular risk factors: migraine, Raynaud's, systemic hypotension, sleep apnea.
- Disc hemorrhages are more common in NTG and are a strong risk factor for progression.
- Exclude secondary causes of normal-tension optic neuropathy: compressive lesions, NAION, inflammatory optic neuropathy.
Differential Diagnosis
- High-tension POAG (IOP > 21 mmHg on diurnal curve)
- Non-arteritic anterior ischemic optic neuropathy
- Compressive optic neuropathy
- Inflammatory optic neuropathy
- Hereditary optic neuropathy (Leber's)
Evidence-Based Management
IOP reduction remains the only proven treatment — the Collaborative Normal-Tension Glaucoma Study demonstrated that a 30% IOP reduction slows progression. Prostaglandin analogues are first-line. Addressing vascular risk factors is important: avoid nocturnal hypotension (review antihypertensive dosing timing), treat sleep apnea, manage migraine. Calcium channel blockers have been studied for their vasodilatory effects on optic nerve blood flow.
Monitoring & Follow-Up
More frequent monitoring than high-tension POAG is often appropriate given the IOP-independent progression risk. Disc hemorrhages at any visit warrant increased monitoring frequency.
Clinical Pearls
- NTG is not "safe" glaucoma — it can progress rapidly despite normal IOP.
- Evaluate for systemic vascular risk factors at every NTG visit — they are modifiable contributors to progression.
- Disc hemorrhages are a red flag — they indicate active disease and warrant urgent reassessment of the management plan.
- Nocturnal hypotension is an underappreciated risk factor — review antihypertensive medication timing with the patient's primary care physician.
Related Therapeutics — Clinician's Companion
- Glaucoma Therapeutics — Prostaglandins, Rho Kinase Inhibitors (Clinician's Companion)
Key References
- 1.Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression. Am J Ophthalmol. 1998.
- 2.Flammer J, et al. The impact of ocular blood flow in glaucoma. Prog Retin Eye Res. 2002.
This entry is an educational reference designed to support clinical reasoning and awareness. It does not constitute medical advice, establish a standard of care, or replace individualized patient assessment. Clinicians should consult current guidelines and applicable clinical resources when making patient care decisions.